Key Points
In patients with AF on dialysis, the incidence of stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription.
In patients with AF on dialysis who were on a P2Y12 inhibitor, apixaban increased the risk of bleeding, compared with no anticoagulation.
The incidence of MI or ischemic stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription status.
Abstract
This is an Early Access article. Please select the PDF button, above, to view it.
- Received April 25, 2022.
- Revision received July 25, 2022.
- Accepted July 25, 2022.
- Copyright © 2022 American Society of Nephrology
Apixaban with P2Y12 inhibitors in dialysis
Jump to section
More in this TOC Section
Cited By...
- No citing articles found.